Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal

Deal Worth Up To $2.37bn

Executive Summary

As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.

You may also be interested in...



Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen

Plus deals involving Novartis/DTx, Neurogene/Neoleukin, Travere/Mirum, Sanofi/Scribe, Korro Bio/Frequency, MaxCyte/viTToria and more.

Bayer Advances Parkinson’s Cell And Gene Therapies Into First Human Studies

As Biogen makes history in Alzheimer’s, Bayer is aiming for a breakthrough in Parkinson’s, another major target in neuroscience.

Biogen Builds Out Parkinson's Pipeline With Denali Deal

Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC141747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel